Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 07, 2009 13:30 ET | Source: Penwest Pharmaceuticals Co.

Penwest Files Definitive Proxy Materials in Connection With June 10 Annual Meeting

DANBURY, Conn., May 7, 2009 (GLOBE NEWSWIRE) -- Penwest Pharmaceuticals Co. (Nasdaq:PPCO) announced today that it has filed its definitive proxy statement with the U.S. Securities and Exchange...
May 07, 2009 08:00 ET | Source: Penwest Pharmaceuticals Co.

Penwest Reports First Quarter 2009 Financial Results

DANBURY, Conn., May 7, 2009 (GLOBE NEWSWIRE) -- Penwest Pharmaceuticals Co. (Nasdaq:PPCO) today announced its financial results for the first quarter of 2009. Compared with the first quarter of 2008,...
April 29, 2009 13:00 ET | Source: Penwest Pharmaceuticals Co.

Penwest First Quarter 2009 Financial Results Conference Call

DANBURY, Conn., April 29, 2009 (GLOBE NEWSWIRE) -- Penwest Pharmaceuticals Co. (Nasdaq:PPCO) will conduct a conference call on Thursday, May 7, 2009, at 11:00 a.m. EDT to review its financial results...
March 12, 2009 08:00 ET | Source: Penwest Pharmaceuticals Co.

Penwest Sends Letter to Shareholders On Financial, Business and Corporate Governance Developments

DANBURY, Conn., March 12, 2009 (GLOBE NEWSWIRE) -- Penwest Pharmaceuticals Co. (Nasdaq:PPCO) today sent a letter to its shareholders in which the Company provided an update on its recent financial and...
March 11, 2009 09:30 ET | Source: Penwest Pharmaceuticals Co.

Penwest to Present At Cowen & Company 29th Annual Healthcare Conference

DANBURY, Conn., March 11, 2009 (GLOBE NEWSWIRE) -- Penwest Pharmaceuticals Co. (Nasdaq:PPCO) today announced that Jennifer Good, President and Chief Executive Officer of Penwest, will be presenting at...
March 04, 2009 07:30 ET | Source: Penwest Pharmaceuticals Co.

Penwest Reports Fourth Quarter and Year End 2008 Financial Results

Operating Costs Reduced by 30% 2009 Guidance for Revenues of $22 Million to $24 Million and for Net Loss of $1 Million to $3 Million Reflects Increased Royalties From ...
February 25, 2009 08:00 ET | Source: Penwest Pharmaceuticals Co.

Penwest Begins Phase Ib Clinical Trial of A0001, Dosing Underway of Compound for the Treatment of Mitochondrial Diseases

DANBURY, Conn., Feb. 25, 2009 (GLOBE NEWSWIRE) -- Penwest Pharmaceuticals Co. (Nasdaq:PPCO) today announced that it has begun dosing in a Phase Ib clinical trial of A0001, a compound the Company is...
February 23, 2009 12:05 ET | Source: Penwest Pharmaceuticals Co.

Penwest Fourth Quarter and Year End 2008 Financial Results Conference Call

DANBURY, Conn., Feb. 23, 2009 (GLOBE NEWSWIRE) -- Penwest Pharmaceuticals Co. (Nasdaq:PPCO) will conduct a conference call on Wednesday, March 4, at 11:00 a.m. EST to review its financial results for...
February 04, 2009 16:15 ET | Source: Penwest Pharmaceuticals Co.

Penwest to Present At 11th Annual BIO CEO & Investor Conference

DANBURY, Conn., Feb. 4, 2009 (GLOBE NEWSWIRE) -- Penwest Pharmaceuticals Co. (Nasdaq:PPCO) today announced that Jennifer Good, President and Chief Executive Officer of Penwest, will be presenting at...
January 22, 2009 16:15 ET | Source: Penwest Pharmaceuticals Co.

Penwest Sets Focused Priorities for 2009; Takes Actions to Further Reduce Costs

DANBURY, Conn., Jan. 22, 2009 (GLOBE NEWSWIRE) -- Penwest Pharmaceuticals Co. (Nasdaq:PPCO) today announced that its Board of Directors and senior management have set narrowed priorities for 2009, and...